143 related articles for article (PubMed ID: 34207707)
1. Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria.
Tachkov K; Mitkova Z; Milushewa P; Petrova G
Healthcare (Basel); 2021 Jun; 9(6):. PubMed ID: 34207707
[TBL] [Abstract][Full Text] [Related]
2. Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria.
Tachkov K; Mitkova Z; Boyadzieva V; Petrova G
Pharmaceuticals (Basel); 2021 Jan; 14(1):. PubMed ID: 33466766
[TBL] [Abstract][Full Text] [Related]
3. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
[TBL] [Abstract][Full Text] [Related]
4. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S
Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785
[No Abstract] [Full Text] [Related]
5. Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis.
Manova M; Savova A; Vasileva M; Terezova S; Kamusheva M; Grekova D; Petkova V; Petrova G
Front Pharmacol; 2018; 9():1070. PubMed ID: 30294275
[TBL] [Abstract][Full Text] [Related]
6. Production costs and potential prices for biosimilars of human insulin and insulin analogues.
Gotham D; Barber MJ; Hill A
BMJ Glob Health; 2018; 3(5):e000850. PubMed ID: 30271626
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar Insulin and Costs: What Can We Expect?
Heinemann L
J Diabetes Sci Technol; 2015 Sep; 10(2):457-62. PubMed ID: 26350722
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.
Lee HJ; Han E; Kim H
Appl Health Econ Health Policy; 2020 Aug; 18(4):557-566. PubMed ID: 31930450
[TBL] [Abstract][Full Text] [Related]
9. Drug Development and Potential Regulatory Paths for Insulin Biosimilars.
Minocha M; Gobburu J
J Diabetes Sci Technol; 2014 Jan; 8(1):14-19. PubMed ID: 24876531
[TBL] [Abstract][Full Text] [Related]
10. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis.
Bocquet F; Paubel P; Fusier I; Cordonnier AL; Le Pen C; Sinègre M
Appl Health Econ Health Policy; 2014 Jun; 12(3):315-26. PubMed ID: 24578185
[TBL] [Abstract][Full Text] [Related]
11. Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.
Vandenplas Y; Simoens S; Van Wilder P; Vulto AG; Huys I
Front Pharmacol; 2021; 12():644187. PubMed ID: 33953678
[No Abstract] [Full Text] [Related]
12. Update on Biosimilar Insulins: A US Perspective.
Zhang RM; Puri R; McGill JB
BioDrugs; 2020 Aug; 34(4):505-512. PubMed ID: 32681425
[TBL] [Abstract][Full Text] [Related]
13. Biosimilar insulins are coming: what they are, what you need to know.
Edelman S; Polonsky WH; Parkin CG
Curr Med Res Opin; 2014 Nov; 30(11):2217-22. PubMed ID: 25105307
[TBL] [Abstract][Full Text] [Related]
14. The Expiry of Humira
Moorkens E; Godman B; Huys I; Hoxha I; Malaj A; Keuerleber S; Stockinger S; Mörtenhuber S; Dimitrova M; Tachkov K; Vončina L; Palčevski VV; Achniotou G; Slabý J; Popelková L; Kohoutová K; Bartels D; Laius O; Martikainen JE; Selke GW; Kourafalos V; Magnússon E; Einarsdóttir R; Adams R; Joppi R; Allocati E; Jakupi A; Viksna A; Greičiūtė-Kuprijanov I; Vella Bonanno P; Suttorp V; Melien Ø; Plisko R; Mardare I; Meshkov D; Novakovic T; Fürst J; Zara C; Marković-Peković V; Grubiša N; Befrits G; Puckett R; Vulto AG
Front Pharmacol; 2020; 11():591134. PubMed ID: 33519450
[No Abstract] [Full Text] [Related]
15. Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure.
Vogler S; Schneider P; Zuba M; Busse R; Panteli D
Front Pharmacol; 2021; 12():625296. PubMed ID: 34248615
[No Abstract] [Full Text] [Related]
16. Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly.
Stajszczyk M; Batko K; Żuber ZM; Kwiatkowska B; Krajewska-Włodarczyk M; Batko B
BioDrugs; 2024 Jun; ():. PubMed ID: 38861154
[TBL] [Abstract][Full Text] [Related]
17. Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators.
Maksabedian Hernandez EJ; Graf M; Portelli A; Shafrin J
J Med Econ; 2022; 25(1):1118-1126. PubMed ID: 35965481
[TBL] [Abstract][Full Text] [Related]
18. The biosimilar insulin landscape: current developments.
Lavalle-González FJ; Khatami H
Postgrad Med; 2014 Oct; 126(6):81-92. PubMed ID: 25414937
[TBL] [Abstract][Full Text] [Related]
19. Introduction of biosimilar insulins in Europe.
Davies M; Dahl D; Heise T; Kiljanski J; Mathieu C
Diabet Med; 2017 Oct; 34(10):1340-1353. PubMed ID: 28608570
[TBL] [Abstract][Full Text] [Related]
20. Projected US savings from biosimilars, 2021-2025.
Mulcahy A; Buttorff C; Finegold K; El-Kilani Z; Oliver JF; Murphy S; Jessup A
Am J Manag Care; 2022 Jul; 28(7):329-335. PubMed ID: 35852882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
